This is great news!
The important facts to know about this trial: it is first line (anthracycline naïve pts) and only about 15% of soft tissue sarcomas respond to anthracyclines (i.e. doxorubicin).
It is also relatively rare. So a successful trial will be a slam dunk for orphan drug designation from the FDA.
Given the pre-clinical evidence and the evidence from the compassionate use programme, confidence should be very high for a successful trial.
Sarcoma trial to start Nov 15, page-3
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $21.04M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 72463 | 6.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.2¢ | 8810 | 1 |
View Market Depth
| Last trade - 10.16am 29/07/2024 (20 minute delay) ? |
| NOX (ASX) Chart |
Day chart unavailable